MedTrace Logo

Zushima Plaster for Treating Knee Osteoarthritis

NCT02770950 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2018-11-20

No results posted yet for this study

Summary

The purpose of this study is to further evaluate the clinical efficacy and safety of Zushima plaster for patients in knee osteoarthrosis post-marketing.

Conditions

Interventions

DRUG

Zushima plaster with high dose

Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.

DRUG

Zushima plaster with low dose

Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.

DRUG

Indometacin Cataplasms

Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.

Sponsors & Collaborators

  • Beijing Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Beijing Jishuitan Hospital

    collaborator OTHER

  • Beijing Shijitan Hospital, Capital Medical University

    collaborator OTHER

  • Shanghai Municipal Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Gansu Provincial Hospital

    collaborator OTHER

  • General Hospital of Beijing Military Area

    collaborator UNKNOWN

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Quan Jiang, MD. PhD. · Rheumatology Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02770950 on ClinicalTrials.gov